TC BioPharm (Holdings) plc develops clinical-stage allogeneic gamma-delta T-cell therapies for cancer and other indications through its American depositary shares. Company news centers on TCB008, its unmodified gamma-delta T-cell product line, and ACHIEVE clinical-trial updates in acute myeloid leukemia, myelodysplastic syndromes/AML, relapse or refractory disease, and minimal residual disease.
Recurring updates also cover use of the company's CryoTC technology for frozen cell-therapy supply, safety and response observations from dosing cohorts, operating changes tied to outsourced production and decentralized drug development, and public-company matters such as ADS trading status and OTC market transition.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TC BioPharm (NASDAQ: TCBP) has outlined its 2023 strategic plan, focusing on the development of its lead product, TCB-008, an allogeneic gamma-delta T cell therapy for cancer. The Company aims to pursue exclusive partnerships for clinical research, enhancing its competitive edge in the evolving cell therapy landscape. TCB-008 is set for FDA IND filing in Q3 2023 for Acute Myeloid Leukemia and will expand into CAR therapy targeting ovarian cancer. With over 313,000 new ovarian cancer cases reported in 2020, the Company is aligning its assets for better market positioning. TCBP is focused on establishing collaborations and increasing its intellectual property portfolio, aiming for a pivotal role in gamma-delta T cell therapies. The CEO emphasized the importance of partnerships and efficient capital management for long-term growth.
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company, is set to participate in the Sequire Investor Summit from April 24-26, 2023, in San Juan, Puerto Rico. This summit offers unique tax advantages for attendees, aimed at enhancing their investment strategies. Keynote panels and training sessions will be led by industry experts, covering the latest trends and best practices.
On April 26, at 11:00 am ET, TC BioPharm management will present on Track 2. The company's focus is on developing gamma-delta T cell therapies for cancer treatment, with ongoing clinical trials targeting acute myeloid leukemia. TC BioPharm is recognized for its allogeneic approach and maintains a robust patent portfolio in this innovative field.